The use of thrombolytic agents in acute myocardial infarction (AMI) has been extensively studied for the past decade and a half and has become the standard of care for most patients presenting early in the course of AMI. Despite this general acceptance, there remains controversy over the choice of thrombolytic, the use of adjunctive anti-platelet and anti-thrombotic agents, the proper role for PTCA, especially direct PTCA, and the potential role for new interventional devices.
The intent of this article is to examine in turn each of these areas, reviewing selected data from relevant trials. In so doing we shall develop an overall concept for reperfusion in AMI to guide our ongoing efforts at resolving our remaining therapeutic challenges.
Thrombolytic Data GISSI 1 was the first large trial to demonstrate a significant reduction in AMI mortality from treatment with a thrombolytic-streptokinase (1) . The Thrombolysis in Myocardial Infarction (TIMI) Phase 1 study group then compared streptokinase (SK) to recombinant tissue plasminogen activator (rt-PA) in terms of opening efficacy (2) . TIMI 1 demonstrated that 90 minutes after beginning intravenous infusion, the infarct artery patency for SK was 31% and for it-PA was 62%. These results suggested that it-PA would be superior to SK if patency rates at 90 minutes could be considered a surrogate for mortality and/or myocardial salvage.
The TIMI group then continued with a Phase 2 trial designed to determine the role of adjunctive PTCA in patients receiving I.V. it-PA. In the TIMI 2A study we showed that after 100 mgm. I.V. rt-PA given within 4 hours of symptom onset, immediate PTCA offered no reduction in mortality or re-infarction and no salvage in left ventricular ejection fraction (LVEF) compared to PTCA delayed for 18-48 hours (3) . In exchange for no net improvement in clinical outcome, an increase in transfusion requirements and coronary artery bypass grafting (CABG) with immediate PTCA was found.
The trial was continued as the TIMI 2B study in order to determine whether delayed PTCA as a strategy had any advantage over a more conservative strategy of intervention only in case of provocable or spontaneous recurrent ischemia (4). Analysis of invasive versus conservative strategy patients showed no difference with regard to death or non-fatal re-infarction at hospital discharge or 6 week follow-up and no difference in radionuclide LVEF at rest at discharge or 6 week follow-up. One year mortality was identical in both groups (5).
We have subsequently reported that recurrent MI and other ischemic events in the 1 year follow-up are also identical in both groups as a whole (6). Only one subgroup appeared to derive benefit from as invasive strategy. those patients with a history of prior AMI. Here, invasive versus conservative strategy yielded a 42 day mortality of 6.0% versus 11.5% (p 0.04) and one year mortality of 10.3% versus 17.0% (p 0.03). Data such as this led us to conclude that a strategy of "watchful waiting" was appropriate for most patients with AMI after treatment with I.V. it-PA, aspirin, and heparin while an invasive strategy may be appropriate for patients with a history of prior AMI.
The TIMI trial was performed with I.V. rt-PA. This drug was chosen because previous investigation had demonstrated that it had a superior 90 minute patency rate to streptokinase (2) . At that time there was a strong belief, now challenged, that 90 minute patency was a surrogate, or acceptable substitute, for mortality as an end point. Since completion of the TIMI trial, several reports have appeared suggesting that other lytic agents (streptokinase, urokinase, APSAC) may have similar short and/or long term mortality results to rt-PA. The SWIFT trial (should We Intervene Following Thrombolysis) enrolled 800 patients who received APSAC I.M. in the early phase of AMI (7). They were randomized in a fashion similar to TIMI 2B to an aggressive catheterization/PTCA strategy versus a conservative strategy.
This trial showed an early patency rate of 68% with APSAC, which was very similar to rt-PA data. Death at hospital discharge was similar in both groups (aggressive 3.3%, conservative 2.7%) as was 1 year mortality (aggressive 5.8%, conservative 5.0%). Thus, SWIFT appears to confirm the results of TIMI 2 regarding a conservative strategy after I.V. thrombolytic therapy, and it extends these observations to APSAC.
The use of urokinase (UK) as a lytic agent has been most extensively evaluated in Japan, with recanalization rates of 65-70% being achieved after I.V. or I.C. use, 10-42 day reocclusion rates of 14-18%, and in hospital mortality rates of 4-7% (8-10). In Germany, Neuhaus confirmed these data in the GAUS trial (German Activator Urokinase Study) which compared I.V. UK to I.V. rt-PA (11). In this comparison, 90 minute patency with TIMI flow grade 2 or 3 was better with UK than rt-PA in patients treated within 3 hours of symptom onset (70% UK versus 63.9% rt-PA). On the other hand, 90 minute TIMI grade 2 or 3 flow was better in the rt-PA group when treatment began after 3 hours (591% UK versus 77.2% rt-PA). Overall, the UK and it-PA groups were similar with regard to LV function, in-hospital re-infarction, and bleeding complications, suggesting that UK may be equivalent to it-PA in achieving myocardial salvage in AMI. Reocclusion during the first 24 hours may be less frequent with UK, however, with an incidence of 6.5% using UK versus 14.8% with rt-PA.
This last observation is of importance, since reocclusion following reperfusion is a serious problem. We have known from studies in the mid and late 1980's that reocclusion occurs in 10-15% of thrombolysed arteries (3, 12, 13) . Just how serious the consequences of reocclusion can be has only been highlighted more recently, however (14). Review of data derived from the TAMI 1-4 trials showed that hospital mortality in 643 patients with sustained reperfusion was 5% while in 90 patients experiencing reocclusion it was 10% (p < 0.05). In these same patients, overall ejection fraction increased 1 unit in the sustained reperfusion group but decreased 2 units in those having reocclusion (p < 0.01). Clearly, reocclusion is one of our most serious post lysis problems and is a challenge we must address in developing our strategies for the 1990's. Solving the problem of reocclusion will require better understanding of the role of vascular endothelium in initiating and maintaining the thrombotic state as well as the development of better anti-platelet and anti-thrombotic drugs. It seems very likely that strategies developed to deal with post thrombolytic reocclusion may also help us in managing post PTCA acute reclosure, a major problem in using PTCA in and around the time of AMI.
The recently completed ISIS-3 trial comparing mortality end points for SK, rt-PA, and APSAC has created much controversy, but has shed additional useful light on the choice of thrombolytic agent (15). In this trial, there was no difference in mortality by agent (SK 10.5% ; rt-PA 10.3% ; APSAC 10.6%). Analysis of stroke did show an excess of probable cerebral hemorrhage with rt-PA and APSAC (4 and 3 patients per 1000 treated, respectively), although trial design did not require confirmation of cerebral hemorrhage by CAT or MRI scanning.
On the other hand, rt-PA caused fewer recurrent infarctions, a surprising finding since nonfibrin specific agents in other trials seemed to have a lower rate of reocclusion, the presumed major cause of re-infarction.
Allergy/hypotension was common with SK and APSAC. The fibrin specific agents caused more bleeding, but there was no difference in major bleeds with any agent. The trial organizers concluded that SK, APSAC, and rt-PA were equally effective in achieving mortality reduction in AMI despite the known lower 90 minute patency rate of SK. In view of equivalent mortality rates, the excess of strokes with the fibrin selective agents "need to be taken more seriously than has sometimes been the case in discussion of the relative merits of different....regimens" (15). The ISIS-3 data regarding relative efficacy of rt-PA and SK is in keeping with the findings of GISSI-2 (16). This multicenter trial randomized 12, 490 patients with acute MI within 6 hours of symptom onset to receive either rt-PA or SK and additionally randomized them to receive either aspirin alone or aspirin plus 12,500 units of subcutaneous heparin twice daily begun 12 hours after the end of thrombolytic infusion. The end point was the combined estimate of death plus severe left ventricular damage. No specific differences were noted between the two thrombolytic agents as regards the combined end point (rt-PA 23.1%, SK 22.5%) nor after the addition of heparin to the aspirin regimen (heparin 22.7%, no heparin 22.9%).
A great deal on controversy occurred regarding the use of heparin in the ISIS 3 and the GISSI 2 trials. In the United States, there was a strong feeling that full dose I. V. heparin was essential to prevent reocclusion with subsequent reinfarction and mortality if rt-PA was the lytic agent. Work by the Hsia et al. in the HART group and Bleich et al. was used to support this (17, 18). In the HART (Heparin-Aspirin Reperfusion Trial) study, 205 AMI patients treated with rt-PA were randomly assigned to receive either 80 mg. of concomitant aspirin or an immediate bolus of 5,000 units of heparin followed by full dose I.V. heparin sufficient to maintain the activated partial thromboplastin time (APTT) at 1.5 times control or greater. Coronary arteriography at 7-24 hours (mean 18 hours) later showed infarct artery patency in 52% of the aspirin group and 82% of the heparin group (p < 0.0001). Furthermore, in the heparin group, the adequacy of heparinization as judged by the APTT was correlated with the frequency of achieving TIMI grade 2 or 3 flow in the infarct artery (APTT < 45 seconds, TIMI 2 or 3 in 45% patients ; APTT> 45 sec., TIMI 2 or 3 in 88% ; APTT> 60 sec., TIMI 2 or 3 in 95%).
In the trial of Bleich and colleagues, 83 patients with AMI were randomly assigned to receive either rt-PA alone or rt-PA followed by full dose I.V. heparin as described above. Angiography performed 55-59 hours later demonstrated infarct artery patency in 44% of the rt-PA alone group versus 71% of the rt-PA plus heparin group (p= 0.04).
The ISIS 3 and GISSI 2 trials called for subcutaneous heparin begun 12 hours after trial entry, however. This pattern of use with rt-PA is common in Europe but not in the United States.
Subgroup analysis of a small number of North American ISIS-3 patients receiving full dose I.V. heparin compared to the larger sample receiving subcutaneous heparin per protocol showed no difference in mortality. The ISIS-3 study group used this to challenge the importance of heparin usage in determining outcomes with rt-PA.
This issue remains unresolved at the present time, but the ongoing GUSTO trial (Global Utilization of Streptokinase and TPA in Occluded coronary arteries) has created a heparin randomization scheme to try and answer this question.
This large trial is comparing full dose front loaded rt-PA to full dose SK to combination tPA and SK reduced doses.
Within the SK arm, a secondary stratification to subcutaneous versus full dose I.V. heparin has been made. Results of this trial may help to resolve the ongoing conflict regarding heparin utilization with rt-PA as well as the issue of thrombolytic monotherapy versus combination therapy.
Thus, in the realm of thrombolytic agents, SK, UK, and rt-PA appear to be achieving very similar long term mortality results when used as monotherapy.
It has been suggested, however, that a combination or "cocktail" of fibrin selective and non-selective lytic agents may be better than monotherapy.
Certainly GUSTO is attempting to answer that question.
A smaller study, KAMIT (Kentucky Acute Myocardial Infamction Trial), also used the combination of SK and rt-PA as well as evaluating rescue PTCA in order to find a better lytic strategy (19). In this study of 216 randomized patients, acute patency at 90 minutes was 79% with combination therapy compared to 64% with rt-PA alone (P <0.05) as seen in Table 1 . Combination therapy also tended to be more beneficial than rt-PA monotherapy with regards to reocclusion (3% with combination versus 10% with monotherapy, p = 0.06), reinfarction (0% versus 6%, p= 0.05), and need for emergency CABG (1% versus 6%, p = 0.05).
Another trial which examined combination therapy was TAMI 5 (20). This randomized trial of 287 patients compared rt-PA to UK to combination rt-PA/UK therapy in terms of 90 minute patency rates and also evaluated the used of an aggressive catheterization strategy which permitted the use of rescue PTCA. As seen in Table 1 , TIMI 2 or 3 flow was achieved at statistically equal rates by all three treatments but was best achieved by combination therapy. Once again, combination therapy provided a lower rate of reocclusion by hospital discharge as compared to monotherapy.
We already know how critical reocclusion is. These two trials comparing monotherapy with rt-PA to combination fibrin selective/fibrin non-selective therapy have shown a tendency towards better results with combination therapy.
Despite this, most centers continue to use monotherapy, presumably because it is easier to employ. Perhaps the results of GUSTO will help resolve this issue of whether the results of combination therapy are worth the extra effort compared to monotherapy.
Other important issues in lytic management include the timing of lytic administration and the patient population to which it is offered. Age has been a determining feature for lytic administration in many clinical trials. This has created an unfortunate mind set that older patients are at greater risk from lytic agents than younger ones. Available data do not support this. Table 2 is derived from GISSI 1 and ISIS 2 data relative to mortality effects of SK in patients under and over 75 years as analyzed by Yusuf et al. (1, 21, 22) . As is seen, control mortality is higher in older than younger patients (28.8% versus 10.7%), but the benefit of lytic therapy is still present.
In younger patients, each trial showed a significant reduction in mortality, while in older patients, both trials must be combined to achieve the statistical power to verify mortality reduction. This was achieved with no significant increase in stroke rate. Clearly such data indicate we need to be more aggressive in our use of lytics in older patients.
Timing of lytic administration is also an important issue. Our data from the TIMI trial seen in Table 3 show a significant decrease in 6 week mortality when rt-PA therapy is begun within 1-2 hours of symptom onset compared to 3-4 hours (23). Note alse that with earlier treatment, fewer patients had LVEF's < 35%. Unfortunately, much higher rates of re-infarction and recurrent ischemia in this very early treatment group are seen. This may be related to early re-occlusion with rt-PA monotherapy with the adverse consequences already noted and emphasizes the need for strategies to prevent reocclusion.
The recently reported MITI (Myocardial Infarction Triage and Intervention) trial provides additional important information regarding timing of lysis and intervention (24). In this trial, patients identified by paramedics out of hospital as having AMI were randomized to I.V. rt-PA given on site versus given in the hospital. Out of hospital administration was demonstrated to be safe with no excess of complications and was shown to reduce overall mortality (7% field versus 10% hospital) and first anterior MI mortality (6% field versus 14% hospital) compared to hospital treatment.
Of critical importance was the observation that treatment within 70 minutes of symptom onset reduced mortality by 80% (from 10% to 2%) compared to treatment after 70 minutes. In addition, MI size, as measured by nuclear imaging techniques, was dramatically reduced by very early therapy. This and other similar data emphasize another challenge for the 1990'smethods to speed access to reperfusion through both in and out of hospital means.
One simple means of addressing this challenge is to develop stricter protocols in hospital for administration of thrombolytic agents. Table 4 shows the average delay from hospital arrival to thrombolytic administration as reported by Morrison and colleagues at Hennepin County Table 2 . Aae and thrombolysis.
GISS-1 and ISIS-2. Hospital (25), our own data from Bridgeport Hospital, the 80,000 patient U.S. voluntary National Registry of Myocardial Infarction sponsored by Genentech (26), and MITI hospital data. The Hennepin County and Bridgeport data compare well to historical data gathered from the MITI hospitals as well as concurrent data for non MITI patients at the same institutions. Note, however, the dramatic reduction in time to treatment which occurred for the MITI protocol patients in the same 1990-1991 time frame. This is the result of adherence to a very strict protocol as well as the advantages of accurate pre-hospital diagnosis.
If very early thrombolysis results in dramatic mortality reductions as shown, then every institution should strive to reduce its "door to needle" time to achieve this.
As important as it is to achieve early reperfusion, there is other data which strongly supports the open artery hypothesis that even late reperfusion is beneficial and is better than no reperfusion.
Recent work by Hirayama and colleagues used radio-nuclide techniques to evaluate systolic and diastolic function acutely and chronically following early, late and no reperfusion in AMI patients (27). Early reperfusion (within 6 hours) salvaged systolic function as measured by LVEF significantly better than late reperfusion or no reperfusion (EF acute to chronic 48 to 57 <6 hrs ; 40 to 44> 6 hrs ; 48 to 42 with no reperfusion). Late reperfusion, on the other hand, prevented LV dilatation from the acute to chronic phase (EDVI 54 to 48 early, 49 to 50 late, and 48 to 59 no reperfusion). Since dilatation has to do with diastolic function, this study shows that late reperfusion may have diastolic benefit while early reperfusion has both systolic and diastolic benefit.
Both may translate to long term reduction in sequelae of AMI. We have known for many years that ejection fraction (i.e., systolic function) is an independent predictor of survival after AMI. Thus, we would expect that an intervention which preserves both systolic and diastolic function (e.g., early reperfusion) would have a greater benefit than one which affects only diastolic function (e.g., late reperfusion). The dramatic impact of very early (<1-2 hours) compared to later (3-6 hours) lytic therapy presented above supports this and is consistent with the data of Hirayama. It would be logical to assume that the earlier one induces reperfusion, the greater the relative salvage of systolic function and the greater the overall impact on mortality.
The question of whether late reperfusion results in mortality reduction was first addressed by the ISIS-2 study group (21). When the 17, 187 patients randomized in this trial to receive either SK or no SK and aspirin or no aspirin were examined on the basis of duration of symptoms prior to therapy, a benefit for late treatment was seen. Vascular deaths were reduced by 16% (p= 0.02) by treatment with SK in the 5-12 hour window and by 21% (p= 0.08) in the 13-24 hour window. In terms of absolute mortality, the reduction was from 12.1% with no SK to 10.4% with SK in the 5-12 hour time frame. Despite these results, there was no strong support for extending the treatment window to 12 hours in most centers at that time.
More recently, two other trials have attempted to address the issue of late reperfusion and mortality reduction. The EMERAS (Estudio Multicentrico Estreptoquinase Republicas de America del Sur) trial examined the efficacy of I.V. streptokinase (I.V. SK) given 7-24 hours after symptom onset in AMI (28). This study involved 3586 patients randomized to infusion of 1.5 million units of I.V. SK (N =1774) versus a matching placebo infusion (N = 1812). The in hospital mortality for the two groups was not statistically different in the 7-12 hour cohort (I.V. SK 11.3% versus placebo 12.8%, p=---n.s.) nor in the 13-24 hour cohort (I.V. SK 11.0% versus placebo 10.8%, p= n.s.) The reinfarction rate was similar as well (1.7% SK versus 2.1% placebo).
The trial organizers concluded that administration of I.V. SK more than 6 hours after symptom onset produced no significant mortality benefit. This conclusion is at variance with the results of ISIS-2 noted above.
In contrast, the double-blind, placebo controlled, randomized LATE (Late Assessment of Thrombolytic Efficacy) trial used rt-PA as the lytic agent given 6-24 hours after symptom onset in 5709 patients (29). This trial showed a statistically significant 27% reduction in 35 day mortality with rt-PA treatment in the 6-12 hour time frame (mortality 8.7% rt-PA versus 11.9% with no lytic, p 0.03). In the 12-24 hour time frame there was no mortality benefit for lytic treatment, however. No excess of myocardial rupture or rupture equivalent events was seen with late treatment and no unusual incidence of intracranial hemorrhage was seen. Therefore, in the 6-12 hour time frame information regarding efficacy of SK is conflicting, but the LATE trial shows a clear benefit for rt-PA suggesting this is the probable agent of choice.
Thus, thrombolytic efficacy is now shown for up to 12 hours after symptom onset. Available data, pending the report of the GUSTO trial, suggest essential equivalency of the commonly used thrombolytics in the 0-6 hour window with It-PA being the probable agent of choice in the 6-12 hour period.
The results of therapy in terms of mortality reduction will depend upon the time frame in which therapy occurs. This is illustrated in Fig. 1 These data suggest the following challenges for thrombolytic therapy in 1993. We must make efforts to achieve early reperfusion and must learn to use our agents properly to sustain reperfusion.
Given the present time frame of treatment for most patients, the choice of lytic agent is probably less critical than having a strict protocol for rapid administration of the agent. Expanded used in the elderly and in patients presenting late in their course is supported by present data. Combination lytic regimens seem to be of benefit in reducing reocclusion in hospital and deserve further evaluation as in the GUSTO trial. Additionally, work is needed regarding the proper use of adjunctive platelet and thrombin active agents to help us deal with reocclusion.
The GUSTO trial (evaluating I.V. versus subcutaneous heparin) as well as ISIS 4, TIMI 5 (evaluating hirudin and other antithrombins), and other important ongoing studies are addressing these issues.
Interventional Data TIMI 2 along with SWIFT and TAMI 1 showed conclusively that immediate PTCA does not a have routine role in the post lytic treatment of AMI (3, 7, 30 ). The use of PTCA as direct or primary therapy for AMI is relevant, however. Several of the larger case reports on direct PTCA show a primary success rate of over 92% (31, 32, 33). This approximates the success rate for elective PTCA. The hospital and late mortality in direct PTCA is acceptable with an 8.1% rate reported in these series for hospital rates and late mortality of 5-10% at one year. Unfortunately, these data are not strictly comparable to mortality data in thrombolytic trials because entry criteria for lytic trials often screened out people who would be candidates for direct PTCA. Indeed, direct PTCA is frequently used in patients who are not candidates for lysis, and some data exists to suggest that the direct PTCA patients represent a higher risk pool than those in the lytic trials. To answer this question, a new trial is now being organized which plans to randomize patients excluded from thrombolysis to conventional therapy versus direct PTCA. This trial may answer this most important issue.
Recently, three trials have been reported in which patients with AMI were randomized to either thrombolytic therapy or direct PTCA. The Primary Angioplasty in Myocardial Infarction (PAMI) study group randomized 395 patients presenting within 12 hours of symptom onset to either direct or primary PTCA or I.V. rt-PA, 100 mgm over 3 hours (34). The primary end point of the trial was nonfatal reinfarction or death at 6 months. PTCA was performed in 89.7% of the 195 patients randomly assigned to that group and was successful in 97.1% of them. In hospital reinfarction rate was 2.6% in the PTCA group versus 6.5% in the rt-PA group (p 0.06) and death rate was 2.6% PTCA versus 6.5% rt-PA (p 0.06). The group of patients defined as not low risk (age> 70 years, anterior infarction, or heart rate over 100/minute) as previously defined by the TIMI group (4) derived a more striking in hospital mortality benefit from PTCA (2.0% PTCA versus 10.4% rt-PA, p 0.01) than did the low risk group (3.1% PTCA versus 2.2% rt-PA, p 0.69). This suggests that the major benefit for direct PTCA may be seen in the highest risk patients.
The combined endpoint of 6 month nonfatal reinfarction or death showed a statistically significant advantage for PTCA over rt-PA (8.5% PTCA , 16.8% rt-PA, p 0.02).
A slightly smaller study of 142 patients randomly assigned to either I.V. streptokinase (SK) or direct PTCA revealed a similar conclusion favoring a strategy of direct PTCA over I.V. thrombolytic (35). End points of this trial were recurrent ischemia in hospital, left ventricular ejection fraction, and vessel patency.
The trial was too small to assess mortality differences in a statistically valid fashion. Again, PTCA showed a high degree of primary success at 98.5%. The direct PTCA group demonstrated statistically better outcomes in the end points of recurrent in hospital ischemia (I.V. SK 38% versus PTCA 9%, p< 0.001), left ventricular ejection fraction (I.V. SK 45+ / artery patency (I.V. SK 68% versus PTCA 91%, p 0.001).
A third study randomly assigned 108 patients with AMI to either I.V. rt-PA or direct PTCA (36). In this trial, the primary end point was change in the size of perfusion defect from hospital admission to hospital discharge as assessed by the radionuclide technetium-99 m sestamibi. In this trial, there was no difference in the mean salvage of left ventricular myocardium between the two treatment strategies.
Because of the small size of the trial, however, a small difference between the two therapeutic approaches cannot be excluded entirely.
Of particular note in the two studies whose results favored direct PTCA is the very short time from hospital arrival to angiography/PTCA.
The average time was 60 minutes in the PAMI trial and 61 in the study by Zijlstra and colleagues.
In order to achieve the results of these trials, this very important "door to balloon" time factor must be taken into account.
Such results should not be expected if the time from hospital diagnosis to PTCA is significantly longer than those reported.
Despite the excellent results of direct PTCA, this strategy has a weakness.
When PTCA fails to open the artery, the consequences are serious indeed. Table 5 shows that in 3 large trials, the hospital mortality with success was 5.0% while with PTCA failure it was 32.1% (31-33). This creates a mortality risk ratio of 6.4/1 for direct PTCA failure. The reasons for this are not entirely clear. Perhaps the stress of the procedure or exposure to x-ray dye adds to the AMI burden significantly . Or perhaps patients who fail have intrinsically worse coronary anatomy, although analysis to date has not shown that to be true. In any case, failure is clearly a serious problem. One special area in which direct PTCA has found a clear niche is in the treatment of cardiogenic shock (CGS) . Several series have been reporoted on PTCA use in CGS (31, 37, 38). In these 3 direct PTCA series of 1053 patients, 129 or 12.3% had CGS. The primary success in these 129 patients was 85.3%. PTCA success led to a hospital mortality of 28.2% on average, significantly better than the expected 80-90%.
Unfortunately, once again PTCA failure was an ominous sign, with mortality of 78.9% and a risk ratio of 2.8/1 for death with PTCA failure versus success.
In this case, the mortality rate with failure is no worse than one would expect for routinely treated CGS, so the implications may not be as severe as for failed direct PTCA without CGS.
Clearly, direct PTCA is efficacious therapy for AMI. Unfortunately, most hospitals are not equipped with resources to provide prompt direct PTCA to a significant number of their AMI patients.
As with lytic therapy alone , time is a crucial factor if myocardium is to be saved and systolic function preserved.
The excellent and encouraging results obtained in the PAMI and Zijlstra trials are likely due to the rapidity of performing highly successful direct PTCA. This places their patients within Zone 1 or early Zone 2 as defined in Fig. 1 , the area where greatest mortality and ventricular function salvage should occur. Most institutions which perform PTCA do not have the logistic support to achieve such short "door to ballon" times on a regular basis. Therefore, for most this treatment strategy is attractive and effective, but it is applicable to only a small minority of patients.
The setting of AMI with CGS is perhaps the clearest imperative to perform direct PTCA if it is available.
In addition, patients who are "not low risk" as defined by TIMI may also be excellent candidates.
Whether or not it is appropriate treatment for thrombolytic ineligible patients awaits the results of a newly formed trial.
More controversial than direct PTCA is rescue PTCAthat is, PTCA performed for persistently occluded vessels after a lytic agent has been given. Several trials provide information regarding safety and efficacy of rescue PTCA. The TAMI 5 trial referred to earlier required rescue PTCA for occluded arteries in the aggressive cath arm if the anatomy was appropriate (20). Of the 69 patients in TAMI 5 with occluded arteries, 52 underwent rescue with full success in 82.7% and partial success in 5.8%. Of the patients leaving the cath lab with patent arteries, 6 later reocciuded for a rate of 13%. Of particular interest, however, was that no (0%) reocclusion occurred in the group of patients with combination rt-PA/UK therapy. Unfortunately, the numbers are so small that a meaningful conclusion cannot be drawn from this. This finding is consistent with the non-rescue TAMI 5 reocclusion rate of only 2% with combination rt-PA/UK therapy and with the low 24 hour reocclusion rate of 1.6% in the GAUS trial with UK. In any upcoming rt-PA trial in which rescue PTCA is permitted, it would be interesting to design a randomization in which patients were assigned to monotherapy with rt-PA or added therapy with a fibrin non-selective agent such as UK or SK to gain further insight into this matter.
The TAMI 5 investigators concluded that the combination of rt-PA and UK worked very well but it was unknown whether SK or antiplatelet/antithrombin agents could equal UK. While an aggressive catheterization strategy might result in improved clinical outcomes, further work was needed on noninvasive tests to determine lack of reperfusion early after lytic therapy. This would aid in identifying patients for rescue PTCA and avoid having to catheterize all patients.
Thus, another challenge for the 1990's is the development of better noninvasive tests to detect lytic failure quickly and guide rescue PTCA efforts. Perhaps isoform CK-MB, digital analysis of ST segments, or other investigative will provide an answer.
In the TIMI 2 experience, we recently reviewed our data relative to rescue PTCA. The rescue patients come from the TIMI 2A population and the non-rescue patients from TIMI 1. Entry criteria were the same for both trials. Among patients studied acutely after rt-PA, 149 had persistently occluded infarct arteries. Of these 149, 38 underwent rescue PTCA and 111 did not. Time from symptom onset to rt-PA was 3.3 hours in the rescue versus 4.7 hours in the non-rescue group (p < 0.001). At 21 days of follow-up there was no statistical difference in clinical outcomes of death (7.2% rescue, 13.2% non-rescue, p 0.26) or re-infarction (5.4% rescue, 10.5% nonrescue, p 0.28). Hospital discharge ejection fraction was also similar (47.7% rescue, 49.3% non-rescue, p> 0.20). Thus, in the TIMI experience rescue PTCA, although usually successful angiographically, did not appear to reduce mortality or enhance myocardial salvage.
These data along with data from TAMI trials (13, 20, 30), the ECSG (12), and Toho University (39) are shown in Table 6 . The average primary success rate of 84.3% was similar to that of immediate PTCA but reocclusion averaged a high 22.6% and may have contributed to the overall mortality rate of 9.4%. This rate is 50% higher than with successful direct PTCA or successful thrombolysis alone in the TIMI trial. As with direct PTCA both with and without CGS, failure of rescue PTCA carries with it unfortunate consequences.
Mortality with success was 6.1% while PTCA failure foretold a 35.7% mortality, a mortality risk ratio of 5.9/1.
A recurring theme for PTCA in the setting of AMI is that failure carries with it a serious in hospital mortality risk. Table 7 summarizes the data which have just been presented.
The numbers of patients in the direct, rescue and CGS groups are noted at the top. PTCA success rates are noted along with mortality rates in this group followed by the PTCA failure patients with their mortality. On the bottom we can see the risk ratio for death that PTCA failure brings-6.4 for direct without CGS ; 5.9 for rescue ; 2.8 for CGS. As noted before, the reasons for this increase in mortality with procedure failure are not clear and further understanding is needed. Certainly acute reocclusion in the cath lab plays a significant role. All of us know that PTCA of unstable plaques is more likely to lead to acute reclosure than dilation of a stable plaque.
In 1986, our data at Bridgeport Hospital showed a reclosure rate of 3.2% in elective, 7.8% in urgent (unstable angina, impending AMI), and 13.5% in AMI PTCA. Reclosure remained fixed in 1.4% of elective, 3.9% of urgent, and 3.8% of acute cases. Thus, the risk of permanent reclosure was increased 3 fold when the dilated plaque was already unstable.
These data are summarized in Table 8 .
Strategies to deal with reocclusion are clearly needed to enhance the efficacy of non-thrombolytic intervention in AMI. For many years we have used intra-aortic balloon pumping (IABP) to help maintain patency in difficult PTCA complicated by dissection and/or thrombotic reclosure.
Very elegant work reported by Ishihara and colleagues has shed light on the mechanism of IABP benefit. (40, 41). In their reports, reocclusion was significantly reduced from 17.7% to 2.4% in one series of patients.
In another series of patients undergoing PTCA for AMI, Doppler flow studies suggested that the mechanism for this already demonstrated benefit might be a significant increase in peak coronary blood flow without change in mean coronary blood flow velocity. Such an increase might make platelet and fibrin deposition more difficult and subsequent re-closure less likely.
Pharmacologic adjuncts to lysis and angioplasty intervention are of critical importance to advancing our quest for sustained early infarct artery patency. This is another major challenge for the 1990's. Reocclusion after successful reperfusion limits the overall effectiveness of current treatment techniques and, as we have seen, is seemingly related to mortality in both lytic and intervention trials. Resistance to thrombolysis may in part be due to the ratio of red cells to platelets in the occlusive clots of AMI. Plaque fissuring with high rbc/fibrin clots responds well to lytics. On the other hand, plaque rupture with high platelet/rbc clots responds less well. Inhibition of platelets and their chemical attractants is an important avenue of present and future research.
For the present, however, understanding the proper use of existing drugs, including aspirin, is vital.
Many factors act to stimulate platelet aggregation, but in AMI it seems likely that the stimulus is a potent one such as a subintimal collagen exposure.
There is evidence that low dose aspirin (ASA) inhibits thromboxane production but does not fully inhibit platelet aggregation. The full effects of low dose ASA on aggregation develop cumulatively over several days in any case. At 24 hours after 100 mg ASA, only a small portion of the inhibitory effect is seen.
This was demonstrated in work by Kuster in which platelet aggregation in response to collagen was assessed in normal volunteers after different daily doses of ASA (42). They showed that 24 hours after 25, 50,100 , and 500 mgm. of oral aspirin, baseline platelet aggregation was inhibited by 10%,18%, 25%, and 75% respectively. It took 2 days for 100 mgm/day of aspirin to reduce platelet aggregation by 65% and 4 days to reduce it by 75%. It is evident that to a potent stimulus like collagen , low doses of ASA achieve only partial reduction of aggregation, and what is achieved occurs over a period of several days. Data such as these become important when we realize that a drug such as rt-PA appears to activate platelets in the setting of AMI. In the ECSG, low doses of ASA were associated with a high rate of reocclusion, while higher doses markedly reduced reocclusion in the setting of early PTCA. When the TIMI 2B data are reviewed, it is clear that the vast majority of patients had received only 80 mg of ASA when immediate PTCA was performed. In view of the Kuster data, this suggests that platelets may have been inadequately inhibited at the time early PTCA was performed. We in TIMI acknowledged in our article that death and non-fatal recurrent MI occurred early, especially in invasive patients, and that this suggested a procedurally related event. Perhaps it was as simple as ASA dosing.
ISIS 2 showed us very clearly that ASA was as potent as SK in reducing mortality post AMI and that maximal effects depended on both agents being used together (21). Perhaps previously reported immediate PTCA results might be skewed by inattention to proper ASA and antiplatelet therapy.
Certainly, much work on antiplatelet and antithrombin drugs including hirudin, GP Ilb/Illa antagonists, prostacyclin analogues such as Iloprost and ciprostene, and other agents is ongoing in an effort to help us stabilize the unstable plaque and create a more conducive micro-environment for lytic and interventional work.
At the present time, none of the new interventional devices have a clear role in AMI intervention. Stents certainly seem inappropriate at the present time since they are thrombogenic and we have already acknowledged the unstable, thrombogenic microenvironment which exists in the AMI plaque.
In the future, some form of stent, perhaps biodegradable, might be impregnated with an anti-platelet/anti-thrombin agent for use in AMI, but at present none of our stents have a role here.
The presently available atherectomy devices (DCA, TEC, Rotablator) do not seem to have any role in AMI. Indeed, the presence of thrombus is one of the contraindications for the use of some of these devices.
One of the hoped for uses of the Spears Laser Balloon was to dehydrate thrombus in AMI. Unfortunately, work on that device has now ceased despite much initial promise. We and others have used the excimer laser coronary angioplasty system of AIS in the presence of thrombotic debris (43). Although it is able to traverse long diseased segments and can be used in the presence of at least moderate amounts of thrombus, as yet there is no clear role for this tool in AMI. The long balloon (e.g. Force balloon, Bard) has been useful in dilating longer plaques while minimizing the risk of dissection.
In AMI work with long diseased segments or saphenous vein grafts with long segments of thrombotic debris, these long balloons have proven very useful.
Perfusion devices may have a role in PTCA in AMI, especially when attempts at PTCA are hampered by thrombotic reocclusion and/or dissection. In these cases, prolonged inflation seems to assist in stabilizing the situation.
Assisted perfusion with perfusion pumps or similar devices may come to have a role if they are simple to use. The existing Bard CPS system has required cannulae which are too large for easy use, unfortunately. As an alternative, we have frequently used the Stack auto-perfusion balloon. This balloon allows prolonged inflation with minimal ischemia.
Such prolonged inflation is sometimes helpful in ironing out thrombotic debris in large vessels.
To summarize the preceding, we can say the interventional challenges for the 1990's include broader application of direct PTCA where available, especially in CGS and "not low risk" cases.
We must develop improved strategies to prevent reocclusion, perhaps such simple ones as assuring that all patients have adequate pretreatment with ASA. We must develop better non-invasive tools to guide us in efforts at rescue PTCA. Digital ECG analysis and isoform CPK-MB analysis are two promising techniques.
Finally, we should continue to seek new devices to help us and to prevent reocclusion. Balloon polymers and/or stent devices impregnated with antiplatelet/anti-thrombin materials or even gene-spliced material to promote plaque regression are possibilities. These and other tools will promote our efforts in achieving and maintaining early patency in AMI patients until such time as we can prevent and cure the underlying disease of atherosclerosis.
Conclusions
The field of thrombolysis and intervention in AMI continues to evolve. Based upon the available information to date, we are justified in drawing the conclusions noted in Table 9 . It appears that the rapid implementation of reperfusion is probably more important that the implement (PTCA balloon, type of lytic agent) used. Despite the encouraging recent reports, thrombolytics will remain the most useful tools for reperfusion because of lack of access to qualified angioplasty laboratories for most patients with AMI. The cost of developing more labs and training more operators and support staff does not appear to be warranted.
Thrombolytics are indicated within 12 hours of symptom onset.
In the 0-6 hour window, most lytics appear comparable, but in the 6-12 hour window only rt-PA appears useful. Despite the existing evidence that lytic "cooktails" of combined fibrin selective and fibrin non-selective agents seem better than monotherapy, most institutions will continue to use monotherapy for the present.
Once a thrombolytic is given, if ischemia does not resolve within 90-120 minutes, serious consideration of rescue PTCA may be warranted.
In this case, it may be prudent to consider creating a combination lytic regimen using both a fibrin selective and a fibrin non-selective agent in order to decrease the chance of post rescue reocclusion.
In the patient given thrombolytic primarily, an invasive strategy with planned catheterization and PTCA seems appropriate if the patient has a history of prior AMI or if there is provocable ischemia on a pre-discharge stress test. If neither of these conditions exist, then a conservative strategy seems indicated.
If at the time of presentation there is evidence of cardiogenic shock (CGS) or if the patient is in the "not low risk" group, then direct PTCA would be appropriate if qualified personnel are available and if reperfusion can be achieved in the next 60-75 minutes. If not, then thrombolytic therapy would be preferable to any delay in achieving reperfusion.
The crucial element is time to reperfusion, and this will be the main element limiting the application of direct PTCA even in those institutions with Addressing these challenges will allow us to continue reducing the mortality and morbidity from AMI.
Addendum
Since the original preparation of this manuscript, several important reports have been published. The GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) group reported on 41,021 patients randomized within 6 hours of symptom onset to one of four thrombolytic regiments : IVSK with intravenous heparin ; IVSK with subcutaneous heparin ; front-loaded rt-PA with IV heparin ; or a combination of IVSK and rt-PA. (44) Overall, there was no difference in 30 day mortality between the two IVSK arms, but rt-PA produced almost 1% lower mortality than IVSK (IVSK 7.3% vs. rt-PA 6.3%). Combination IVSK and rt-PA therapy produced an intermediate mortality of 6.96%. An important part of the trial was an angiographic substudy which clearly demonstrated that re-establishment of TIMI grade 3 flow was the primary determinant of mortality. (45) Patients with TIMI grade 2 flow at 90 minutes, previously categorized as a patent artery in all earlier studies, had a similar mortality to those with TIMI grade 0 and 1 flow. Specifically, at 24 hours mortality was 2.35% with TIMI grade 0 or 1 flow, 2.93% with TIMI grade 2 flow, and 0.89% with TIMI grade 3 flow at 90 minutes. By 30 days the mortality rate was 9.9% for TIMI grade 0, 9.2% for TIMI grade 1, 7.9% for TIMI grade 2, and 4.3% for TIMI grade 3. Thus, rapid establishment of normal flow was clearly the primary determinant of early and 30 day mortality. rt-PA achieved 90 minute TIMI 3 flow more effectively than the other regimens and this appears to be the reason this treatment regimen had an overall 1% mortality benefit over the other regimens tested.
More recently, preliminary results of the PAMI II trial (Primary Angioplasty in Myocardial Infarction) have been released.
This trial confirms the results of the earlier PAMI I trial and indicates that direct PTCA in the setting of AMI has a very high success rate, a low mortality rate, and a low complication rate when successful.
The mechanism of such benefit appears to be the greater degree of TIMI grade 3 flow established by direct PTCA as compared to lytic therapy.
Once again, the greatest benefit was seen in those patients who were the sickest or had the largest amounts of myocardium at risk.
Finally, the EPIC trial and the TIMI 9 trial have reported on the results of the monoclonal antibody to platelet receptor Gp IIb/Illa (EPIC) and hirudin (TIMI 9) in unstable ischemic syndromes.
These agents clearly enhanced stabilization of acute ischemic syndromes.
Use of such receptor antagonists and anti-thrombins is being further evaluated to determine their role in AMI management.
At this point in 1995, it appears that our goal in AMI therapy should be to rapidly and stably restore normal (i.e., TIMI grade 3) coronary flow. Front loaded rt-PA appears to do this more effectively than IVSK regimens.
Direct or primary PTCA is also highly effective when such resources are available.
In either case, however, the focus is upon the rapid use of a reperfusion strategy ; delay must not be tolerated.
In the GUSTO trial, the mortality benefit of shortening time to treatment by 1 hour was approximately the same as the relative benefit of rt-PA over IVSK. This underscores that time to complete reperfusion is the truly critical factor. New anti-thrombin and anti-platelet drugs are now being tested which will undoubtedly be significant in helping us to achieve these goals or rapid and complete reperfusion and to maintain patency once it has been established. 
